Long non-coding RNAs and tyrosine kinase-mediated drug resistance in pancreatic cancer

被引：0
作者：
Li, Dangran [1 ,2 ]
Weng, Shiting [1 ,3 ]
Zeng, Kai [1 ]
Xu, Hanmiao [1 ]
Wang, Wenyueyang [1 ]
Shi, Jinsong [1 ]
Chen, Jinghua [1 ]
Chen, Chen [1 ]
机构：
[1] Jiangnan Univ, Sch Life Sci & Hlth Engn, Key Lab Carbohydrate Chem & Biotechnol, Minist Educ, Wuxi 214122, Peoples R China
[2] Nanjing Univ, Coll Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210029, Peoples R China
[3] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China
来源：
GENE | 2024年 / 895卷
关键词：
LncRNA; MicroRNA; Pancreatic ductal adenocarcinoma; Chemoresistance; Targeted therapy; Tyrosine kinase; ENDOTHELIAL GROWTH-FACTOR; GEMCITABINE RESISTANCE; C-MET; FACTOR RECEPTOR; EXPRESSION; PROMOTES; OVEREXPRESSION; SURVIVAL; CHEMORESISTANCE; PROGRESSION;
D O I：
10.1016/j.gene.2023.148007
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Pancreatic cancer (PC) is one of the most malignant tumors with a dismal survival rate, this is primarily due to inevitable chemoresistance. Dysfunctional tyrosine kinases (TKs) and long non-coding RNAs (lncRNAs) affect the drug resistance and prognosis of PC. Here, we summarize the mechanisms by which TKs or lncRNAs mediate drug resistance and other malignant phenotypes. We also discuss that lncRNAs play oncogenic or tumor suppressor roles and different mechanisms including lncRNA-proteins/microRNAs to mediate drug resistance. Furthermore, we highlight that lncRNAs serve as upstream regulators of TKs mediating drug resistance. Finally, we display the clinical significance of TKs (AXL, EGFR, IGF1R, and MET), clinical trials, and lncRNAs (LINC00460, PVT1, HIF1A-AS1). In the future, TKs and lncRNAs may become diagnostic and prognostic biomarkers or drug targets to overcome the drug resistance of PC.
引用
收藏
页数：11
相关论文
共 108 条
  • [21] Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy
    Cuneo, Kyle C.
    Morgan, Meredith A.
    Griffith, Kent A.
    Hawkins, Peter G.
    Greenson, Joel K.
    Ben-Josef, Edgar
    Lawrence, Theodore S.
    Zalupski, Mark M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (02): : 490 - 497
  • [22] A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
    Daneshmanesh, Amir Hossein
    Hojjat-Farsangi, Mohammad
    Ghaderi, Amineh
    Moshfegh, Ali
    Hansson, Lotta
    Schultz, Johan
    Vagberga, Jan
    Bystrom, Styrbjorn
    Olsson, Elisabeth
    Olin, Thomas
    Osterborg, Anders
    Mellstedt, Hakan
    [J]. PLOS ONE, 2018, 13 (06):
  • [23] Treatment landscape of metastatic pancreatic cancer
    De Dosso, Sara
    Siebenhuener, Alexander R.
    Winder, Thomas
    Meisel, Alexander
    Fritsch, Ralph
    Astaras, Christoforos
    Szturz, Petr
    Borner, Markus
    [J]. CANCER TREATMENT REVIEWS, 2021, 96
  • [24] Antibody-drug conjugates-an emerging class of cancer treatment
    Diamantis, Nikolaos
    Banerji, Udai
    [J]. BRITISH JOURNAL OF CANCER, 2016, 114 (04) : 362 - 367
  • [25] Dysregulation of miRNAs Targeting the IGF-1R Pathway in Pancreatic Ductal Adenocarcinoma
    Dobre, Maria
    Herlea, Vlad
    Vladut, Catalina
    Ciocirlan, Mihai
    Balaban, Vasile Daniel
    Constantinescu, Gabriel
    Diculescu, Mircea
    Milanesi, Elena
    [J]. CELLS, 2021, 10 (08)
  • [26] Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer
    Du, Jing
    He, Yuanqiao
    Wu, Weiquan
    Li, Peng
    Chen, Youwei
    Hu, Zhiming
    Han, Yong
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2019, 71 (02) : 196 - 205
  • [27] Mechanisms of receptor tyrosine kinase activation in cancer
    Du, Zhenfang
    Lovly, Christine M.
    [J]. MOLECULAR CANCER, 2018, 17
  • [28] Oncogenic and Non-Malignant Pancreatic Exosome Cargo Reveal Distinct Expression of Oncogenic and Prognostic Factors Involved in Tumor Invasion and Metastasis
    Emmanouilidi, Aikaterini
    Paladin, Dino
    Greening, David W.
    Falasca, Marco
    [J]. PROTEOMICS, 2019, 19 (08)
  • [29] Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer
    Fan, Jia
    Wei, Qian
    Koay, Eugene J.
    Liu, Yang
    Ning, Bo
    Bernard, Paul W.
    Zhang, Ning
    Han, Haiyong
    Katz, Matthew H.
    Zhao, Zhen
    Hu, Ye
    [J]. THERANOSTICS, 2018, 8 (21): : 5986 - 5994
  • [30] Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway
    Fang, Zhenghuan
    Jung, Kyung Hee
    Yan, Hong Hua
    Kim, Soo-Jung
    Rumman, Marufa
    Park, Jung Hee
    Han, Boreum
    Lee, Ji Eun
    Kang, Yeo Wool
    Lim, Joo Han
    Hong, Soon-Sun
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 47 (05) : 1751 - 1768
12345678910